A hydroxyfattysulfonic acid analog represented by Formula (I): wherein X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH2 or S(O)pCH2 wherein p is 0, 1 or 2; m is an integer of 1 to 5 inclusive; n is an integer of 0 to 4 inclusive;R1 is a C¿1-8? alkyl group, a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with a C3-8 cycloalkyl group, a C1-4 alkyl group substituted with an aryl group or a C1-4 alkyl group substituted with an aryloxy group; R?2¿ is a hydrogen atom or a methyl group; R?1 and R2¿ together with the carbon atom to which they are attached may form a C¿3-8? cycloalkyl group; R?3¿ is a hydrogen atom or a C¿2-8? acyl group; R?4 is OR5 or NHR6¿, wherein R5 is a hydrogen atom, a C¿1-4? alkyl group, an alkali metal, an alkaline earth metal or an ammonium group and R?6¿ is a hydrogen atom or a C¿1-4? alkyl group; or a pharmaceutically acceptable salt or a hydrate thereof. The compounds of the present invention are useful as an elastase release inhibitor.